Management

Clinical presentation, diagnosis, treatment, and prognosis of renal amyloidosis are codified in a recent review. Read More ›

Treatment with tafamidis in patients with transthyretin amyloid cardiomyopathy resulted in delayed structural and functional cardiac changes. Read More ›

Optimal care of patients with amyloidosis requires consideration of gastrointestinal burden and nutritional status, necessitating a multidisciplinary approach with gastroenterology involvement. Read More ›

Results from a recent study showed a high prevalence of cerebral ischemic events in Afro-Caribbean patients with transthyretin-mediated cardiac amyloidosis and shed light on risk factors for ischemic events in amyloidosis. Read More ›

Researchers investigate microvascular function in patients with cardiac amyloidosis using a new, validated method: dynamic retinal vessel analysis. Read More ›

The first study to examine healthcare resource utilization of patients with transthyretin-mediated cardiac amyloidosis versus patients with heart failure reveals consistent use differential. Read More ›

The US Food and Drug Administration (FDA) approved vutrisiran (AMVUTTRA™), an RNA interface therapeutic administered via subcutaneous injection once every 3 months, for adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. Read More ›

Quantitative 99mTc-PYP imaging has potential as a marker of disease burden by providing robust evaluation in patients with transthyretin amyloid cardiomyopathy. Read More ›

Adding daratumumab to bortezomib, cyclophosphamide, and dexamethasone led to higher frequencies of hematologic complete response and survival free from major organ deterioration or hematologic progression in patients with newly diagnosed AL. Read More ›

In patients with light chain amyloidosis and cardiac involvement, treatment with D-VCd resulted in higher rates of cardiac response, with possible improvement in fatigue-related variables. Read More ›

Page 1 of 2

Subscribe to Amyloidosis News

Stay up to date with Amyloidosis News & updates by subscribing to receive the free AMN e‑Newsletter.